Prices delayed ≤15 min
AI Analysis Summary
Eli Lilly and Company Company Overview & Business Model Eli Lilly and Company (LLY) is a prominent player in the global healthcare sector, primarily engaged in the discovery, development, and marketing of pharmaceuticals. Headquartered in Indianapolis, Indiana, the company has a diverse portfolio that includes key products for diabetes management such as Humalog and Trulicity, as well as oncology treatments like Alimta. Eli Lilly's competitive advantages stem from its robust research and development capabilities, extensive patent protections, and a strong brand reputation. The company operates in the Drug Manufacturers - General industry, where it holds a significant market position, particularly in diabetes and oncology drugs. Unique to Eli Lilly is its commitment to innovation and patient-centric solutions, which has allowed it to maintain a leadership role in therapeutic areas with high unmet medical needs. LLY Financial Performance & Revenue Analysis Eli Lilly's financial performance has shown remarkable growth, with revenues soaring to $65.18 billion in the latest fiscal year, representing a substantial increase of 44.7% year-over-year from $45.04 billion. This impressive revenue trajectory follows a steady climb from $34.12 billion in 2023, illustrating the company's successful expansion strategies and product uptake. The gross profit reached $54.13 billion, yielding a gross margin of 83%, which underscores the efficiency of its operations. While specific operating income figures are not available, the net income reported at $20.64 billion reflects a robust net margin of 31.7%. Additionally, earnings per share (EPS) have surged to $22.95, demonstrating a remarkable growth rate of 96% compared to the previous year, affirming the company's strong profitability. Balance Sheet Strength & Debt Analysis Eli Lilly's balance sheet exhibits a solid financial foundation, characterized by total assets amounting to $112.48 billion and total liabilities of $85.94 billion. The company's shareholders' equity stands at $26.54 billion, indicating a healthy equity position. However, with total debt at $42.50 billion, the debt-to-equity ratio is relatively high at 1.60, which may raise concerns about leverage. The current ratio of 1.58 suggests that Eli Lilly is well-positioned to meet its short-term obligations, balancing its debt levels with adequate liquidity. The net debt position, calculated at $35.23 billion, reflects a manageable debt load given its substantial cash reserves of $7.27 billion, indicating that the company is not overly reliant on debt financing. Cash Flow & Capital Allocation Eli Lilly's cash flow generation has been robust, with operating cash flow reported at $16.81 billion, which provides a solid foundation for ongoing operations and strategic investments. The company has achieved a free cash flow of $8.97 billion, reflecting a growth rate of 138.6% year-over-year, indicating an increasing capacity to generate cash after capital expenditures. Eli Lilly's capital allocation strategy includes significant investments in stock buybacks, totaling $4.11 billion, and dividends paid amounting to $5.38 billion, although the absence of a dividend yield may limit appeal for income-focused investors. This capital deployment strategy highlights the company's commitment to returning value to shareholders while sustaining growth through reinvestment in its core business. LLY Valuation Assessment — Is It Overvalued or Undervalued? Eli Lilly's current valuation metrics suggest a premium positioning within the healthcare sector. The price-to-earnings (P/E) ratio stands at 51.57, which is considerably higher than the industry average, indicating that investors are pricing in substantial growth expectations. The price-to-book ratio of 41.98 and price-to-sales ratio of 17.09 further reflect this premium valuation, suggesting that the market anticipates continued strong performance. However, the lack of available forward P/E and PEG ratios limits a comprehensive growth comparison. Given these figures, LLY's valuation implies that investors are confident in the company’s ability to sustain its impressive growth trajectory, but it also raises questions about whether such expectations are overly optimistic. Growth Prospects, Catalysts & Analyst Outlook Looking ahead, Eli Lilly's growth prospects remain bright, driven by its innovative product pipeline and expansion into new markets. The company has strategically positioned itself to capitalize on trends in chronic disease management, particularly with its diabetes portfolio and oncology treatments. Analysts have noted the potential for further revenue growth as new drugs enter the market and existing products gain broader acceptance. While specific analyst estimates are currently unavailable, the company’s historical performance and market dynamics suggest a favorable outlook. Continued investment in research and development will be critical as Eli Lilly seeks to maintain its competitive edge, making it a stock to watch for growth-oriented investors. Risk Factors & Key Considerations for LLY Investors Investors in Eli Lilly should be mindful of several key risks that could impact the company's performance. The high debt burden, reflected in a debt-to-equity ratio of 1.60, raises concerns about financial flexibility, particularly in a rising interest rate environment. Additionally, potential margin compression could arise from increased competition and pricing pressures in the pharmaceutical industry. Regulatory risks also pose a significant threat, as the approval process for new drugs can be unpredictable and time-consuming. Furthermore, with a beta of 0.37, Eli Lilly's stock is less volatile than the broader market, but macroeconomic sensitivities could still affect its performance, particularly in challenging economic conditions. Eli Lilly and Company Investment Outlook for 2026 In conclusion, Eli Lilly presents a compelling investment opportunity for those focused on growth, with its robust financial performance and strong market positioning. The company’s innovative product offerings and impressive revenue growth trajectory suggest it is well-equipped to navigate the evolving healthcare landscape. However, potential investors should remain vigilant regarding its debt levels and the inherent risks associated with the pharmaceutical industry. LLY may be particularly appealing to growth-oriented investors who are willing to accept higher valuations in exchange for potential future gains. Moving forward, maintaining awareness of market developments and Eli Lilly's strategic initiatives will be crucial as the company approaches 2026.
Financial figures come from Eli Lilly and Company's latest annual SEC filing (fiscal year 2025), so they can lag recent quarters. Prices are delayed up to 15 minutes.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyv
Frequently Asked Questions about LLY
What business is Eli Lilly and Company (LLY) in?
Eli Lilly and Company specializes in the discovery, development, and marketing of human pharmaceuticals on a global scale. Their product lineup includes various insulin formulations such as Humalog and Basaglar, catering primarily to diabetes management.
Should you buy LLY stock right now, in 2026?
Considering LLY's price-to-earnings ratio of 51.57, the stock appears to be on the pricier side, especially in the context of its sector. However, with a remarkable revenue growth rate of 44.7%, there is potential for further appreciation, making it a balanced consideration for growth-focused investors.
How big is Eli Lilly and Company and what's its current share price?
Eli Lilly's current share price stands at $1183.46, reflecting its substantial market capitalization of $1.11 trillion. In the past year, the stock has experienced significant fluctuations, with a 52-week high of $1292.65 and a low of $716.08.
Does LLY offer a dividend to investors?
LLY does not distribute dividends to its shareholders, which may influence those seeking steady income from their investments. Instead, the company appears to reinvest its earnings into growth initiatives, as evidenced by its impressive revenue growth.
Is Eli Lilly and Company a profitable company?
Eli Lilly boasts a net income of $20.64 billion, reflecting a robust net margin of 31.7%. Additionally, the company's return on equity (ROE) stands at an impressive 77.8%, and it generates free cash flow of $8.97 billion, further highlighting its financial health.
Is LLY overvalued based on its P/E ratio?
With a P/E ratio of 51.57, LLY appears to be relatively high compared to the broader market and many of its peers in the drug manufacturing sector. This suggests that while investors are optimistic about future growth, they may be paying a premium for those expectations.
How leveraged is Eli Lilly and Company's balance sheet?
Eli Lilly's balance sheet shows a debt-to-equity ratio of 1.60, indicating a moderate level of leverage. However, a current ratio of 1.58 suggests that the company maintains adequate liquidity to cover its short-term obligations.
Where has LLY traded over the past 52 weeks?
In the last year, LLY's stock price has ranged from a low of $716.08 to a high of $1292.65. Currently, at $1183.46, it sits closer to its 52-week high, reflecting strong market performance despite the absence of moving average data.
Would you classify LLY as a growth or value play?
Given Eli Lilly's impressive revenue growth rate of 44.7% and an earnings per share (EPS) of $22.95, it leans more towards a growth stock. The absence of a dividend further emphasizes its focus on reinvestment for future expansion rather than immediate shareholder returns.
What risks should LLY shareholders be watching?
Investors in LLY should be aware of several risks, including its beta of 0.37, which suggests lower volatility compared to the market. Additionally, the company's significant debt levels and the competitive landscape in the healthcare sector could pose challenges to its growth trajectory.